Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer

Study:

A Phase II Evaluation Of Capecitabine (NSC #712807) In The Treatment Of Persistent Or Recurrent Non-Squamous Cell Carcinoma Of The Cervix

Rationale:

Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

Purpose:

Phase II trial to study the effectiveness of capecitabine in treating patients who have persistent or recurrent cervical cancer.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Cervical Cancer Drug: capecitabine Phase 2

Verified by Gynecologic Oncology Group July, 2005

Sponsored by: Gynecologic Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00039442

Study Type: Interventional

Study Design: Treatment

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44124
United States

Katherine Y. Look, MD., Study Chair
Agustin Garcia, MD.,

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site